<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03974074</url>
  </required_header>
  <id_info>
    <org_study_id>Alb-HCC</org_study_id>
    <nct_id>NCT03974074</nct_id>
  </id_info>
  <brief_title>Albumin for Hepatocellular Carcinoma</brief_title>
  <official_title>Albumin Infusion for Patients With Hepatocellular Carcinoma and Hypoproteinemia After Hepatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangxi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rate of liver cirrhosis is about 40% to 75% among patients with hepatocellular carcinoma
      (HCC). Therefore, many patients with HCC were with low serum albumin before and after
      (especially) hepatic resection. Serum albumin level has been routinely used in clinical
      practice as a surrogate marker to evaluate nutritional status and liver function. Serum
      albumin concentration is used as an independent mortality risk predictor in a broad range of
      clinical and research settings. However, the role of albumin infusion in patients with
      hepatocellular carcinoma (HCC) after resection is unknown. The present study aimed to
      investigate the safety and clinical necessity of albumin infusion for HCC patients after
      hepatic resection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum total bilirubin level</measure>
    <time_frame>Change from Baseline total bilirubin at the fifth and seventh days after resection</time_frame>
    <description>Recovery of liver function between the two groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum albumin level</measure>
    <time_frame>Change from Baseline serum albumin at the fifth and seventh days after resection</time_frame>
    <description>Recovery of liver function between the two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abdominal girth</measure>
    <time_frame>Change from Baseline abdominal girth at the fifth and seventh days after resection</time_frame>
    <description>Drainage liquid and abdominal girth between the two groups were compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postoperative complications</measure>
    <time_frame>The first months after resection</time_frame>
    <description>The rate of postoperative complications between the two groups were compared</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hypoproteinemia</condition>
  <arm_group>
    <arm_group_label>Albumin infusion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after hepatic resection in 24 h for three days. All patients wil receive furosemide (10 mg, iv) after albumin transfusion. In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empty control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional liver protection and rehydration therapy.In the fifth day after resection, patients will receive albumin transfusion if they have ascites with shifting dullness, moderate edema (below both lower ankle joints) with serum albumin lower than 30 g/L, severe postoperation complication (septicopyemia, postoperative bleeding with reoperation, or biliary fistula).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin infusion</intervention_name>
    <description>Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after resection in 24 h for three days.</description>
    <arm_group_label>Albumin infusion group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index &gt;18.5;

          -  Patients with primary hepatocellular carcinoma without any treatments for tumors
             before resection;

          -  Hepatocellular carcinoma should be confirmed by histopathology;

          -  With preserved liver function (Child-Pugh score â‰¤7) before resection

          -  ECOG performance score 0 or 1;

          -  Preoperative serum albumin &gt;35g/L;

          -  The level of postoperative serum albumin is between 25-30g/L in the first day after
             resection.

        Exclusion Criteria:

          -  Patients used albumin before liver resection (&lt;1 months);

          -  Plasma was used during or after liver resection;

          -  Surgery involving the extrahepatic bile duct or gastrointestinal tract.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei-Zhong Tang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cancer Hospital of Guangxi Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian-Hong Zhong, PdD</last_name>
    <phone>771 5330855</phone>
    <email>zhongjianhong@gxmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bang-De Xiang, PdD</last_name>
    <email>xiangbangde@gxmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian-Hong Zhong, PdD</last_name>
      <email>zhongjianhong@gxmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jian-Hong Zhong</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jian-Hong Zhong</last_name>
      <phone>771 5330855</phone>
      <email>zhongjianhong@gxmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010 Sep;53(3):397-417. doi: 10.1016/j.jhep.2010.05.004. Epub 2010 Jun 1. Review.</citation>
    <PMID>20633946</PMID>
  </results_reference>
  <results_reference>
    <citation>Pericleous M, Sarnowski A, Moore A, Fijten R, Zaman M. The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations. Eur J Gastroenterol Hepatol. 2016 Mar;28(3):e10-8. doi: 10.1097/MEG.0000000000000548. Review.</citation>
    <PMID>26671516</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>June 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Jian-Hong Zhong</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hypoproteinemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

